APA (7th ed.) Citation

DA, C., GJ, B., MD, S., & GA, A. (2026). Pediatric Hepatic Impairment Dosing in FDA Approvals Between 2002 and 2024. Clinical pharmacology and therapeutics, 119(5), 1257. https://doi.org/10.1002/cpt.70011

Chicago Style (17th ed.) Citation

DA, Cassel, Burckart GJ, Sahre MD, and Abulwerdi GA. "Pediatric Hepatic Impairment Dosing in FDA Approvals Between 2002 and 2024." Clinical Pharmacology and Therapeutics 119, no. 5 (2026): 1257. https://doi.org/10.1002/cpt.70011.

MLA (9th ed.) Citation

DA, Cassel, et al. "Pediatric Hepatic Impairment Dosing in FDA Approvals Between 2002 and 2024." Clinical Pharmacology and Therapeutics, vol. 119, no. 5, 2026, p. 1257, https://doi.org/10.1002/cpt.70011.